3RD-GENERATION CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELLS (CARTS) FOR RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) - UPDATE ON THE ONGOING ACADEMIC PHASE 1/2 TRIAL (HD-CAR-1)

被引：0
|
作者：
Derigs, P. [1 ]
Kunz, A. [1 ]
Dreger, P. [1 ]
Schmitt, A. [1 ]
Schubert, M. -L. [1 ]
Brueggemann, M. [2 ]
Bernhard, H. [3 ]
Kobbe, G. [4 ]
Lindemann, A. [5 ]
Rummel, M. [6 ]
Wang, L. [1 ]
Michels, B. [1 ]
Waldhoff, P. [1 ]
Korell, F. [1 ]
Laier, S. [7 ]
Ho, A. D. [1 ]
Mueller-Tidow, C. [1 ]
Schmitt, M. [1 ]
机构：
[1] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany
[2] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany
[3] Klinikum Darmstadt, Dept Internal Med 5, Darmstadt, Germany
[4] Univ Hosp Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany
[5] Onkol Ettlingen, Praxis Onkol, Ettlingen, Germany
[6] Univ Hosp Giessen, Dept Internal Med 4, Giessen, Germany
[7] German Red Cross Drk Blood Donat Serv Baden Wurtt, Inst Clin Transfus Med & Cell Therapy IKTZ, Heidelberg, Germany
来源：
HUMAN GENE THERAPY | 2023年 / 34卷 / 21-22期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P003
引用
收藏
页码：A7 / A8
页数：2
相关论文
共 50 条
  • [41] Chimeric antigen receptor-modified T cells directed against CD19 in patients with relapsed or refractory CD19-positive B-cell lymphomas: interim analysis of a phase 1 study
    Ying, Zhitao
    Xiang, Xiaoyu
    Song, Yuqin
    Ding, Ning
    Lin, Yufu
    Zheng, Wen
    Wang, Xiaopei
    Lin, Ningjing
    Tu, Meifeng
    Xie, Yan
    Zhang, Chen
    Liu, Weiping
    Deng, Lijuan
    Liu, Yanling
    Yue, Yunqiang
    Yu, Xueyun
    Liu, Hanzhi
    Duan, Panpan
    Mamuti, Mierzhati
    Guo, Xiaokai
    Chen, Feng
    Wu, Xiaoyan
    Zhang, Junqing
    Zhang, Tingting
    Huang, Xue F.
    Jones, Lindsey
    Kang, Xi
    Chen, Si-Yi
    Zhu, Jun
    LANCET ONCOLOGY, 2017, 18 : S9 - S9
  • [42] Hypogammaglobulinemia and Infection Risk in Relapsed Refractory B Cell Malignancy Patients Treated with Varnimcabtagene Autoleucel (IMN-003A), a CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in the Phase-2 Study (IMAGINE)
    Damodar, Sharat
    Bhat, Sunil
    Thirumalairaj, Raja
    Malhotra, Pankaj
    Nayak, Akshatha
    Mallya, Pooja
    Joshi, Ravi
    Raj, Revathy
    Ahamed, Rameez
    Singh, Charanpreet
    Raja, B.
    Arasu, Pallavi
    Elluru, Sri Ramulu
    Akheel, Mohammed Manzoor
    Kamat, Anil
    BLOOD, 2023, 142
  • [43] Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE)
    George, Philip
    Dasyam, Nathaniel
    Giunti, Giulia
    Mester, Brigitta
    Bauer, Evelyn
    Andrews, Bethany
    Perera, Travis
    Ostapowicz, Tess
    Frampton, Chris
    Li, Peng
    Ritchie, David
    Bollard, Catherine M.
    Hermans, Ian F.
    Weinkove, Robert
    BMJ OPEN, 2020, 10 (02):
  • [44] Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
    Zhou, Xuan
    Tu, Sanfang
    Wang, Chunsheng
    Huang, Rui
    Deng, Lan
    Song, Chaoyang
    Yue, Chunyan
    He, Yanjie
    Yang, Jilong
    Liang, Zhao
    Wu, Anqin
    Li, Meifang
    Zhou, Weijun
    Du, Jingwen
    Guo, Zhenling
    Li, Yongqian
    Jiao, Cheng
    Liu, Yuchen
    Chang, Lung-Ji
    Li, Yuhua
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [45] Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)
    Shah, Bijal D.
    Stock, Wendy
    Wierda, William G.
    Oluwole, Olalekan
    Holmes, Houston
    Schiller, Gary J.
    Topp, Max S.
    Kersten, Marie Jose
    Houot, Roch
    Boissel, Nicolas
    Mojadidi, Michelle
    Xue, Allen
    Mardiros, Armen
    Jiang, Yizhou
    Shen, Tong
    Aycock, Jeff S.
    Stout, Shanna
    Wiezorek, Jeffrey S.
    Jain, Rajul
    BLOOD, 2017, 130
  • [46] EXPLORING THE ROLE OF INDIGENOUSLY DEVELOPED NOVEL HUMANIZED CD19-DIRECTED CHIMERIC ANTIGEN RECEPTOR(HCAR19) T-CELLS FOR RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA- A PILOT OPEN-LABEL SINGLE-ARM PHASE-I STUDY
    Narula, Gaurav
    Purwar, Rahul
    Jain, Hasmukh
    Dhamne, Chetan
    Tembhare, Prashant
    Pg, Subramanian
    Patkar, Nikhil
    Poojary, Minal
    Nisar, Albeena
    Pandit, Deepali
    Karulkar, Atharva
    Rafiq, Afrin
    Khan, Aalia
    Jaiswal, Ankesh
    Suvasia, Prashant
    Asija, Sweety
    Suvasia, Priyanshi
    Pendhari, Juber
    Shah, Shreshtha
    Moulik, Nirmalya Roy
    Swaminathan, K.
    Bhosle, Shilpushp
    Hiregoudar, Sumathi
    Ojha, Shashank
    Nayak, Lingaraj
    Thorat, Jayashree
    Bagal, Bhausaheb
    Sengar, Manju
    Jindal, Nishant
    Chichra, Akanksha
    Mirgh, Sumeet
    Gokarn, Anant
    Punatar, Sachin
    Rajadhyaksha, Sunil
    Khattry, Navin
    Banavali, Sripad
    PEDIATRIC BLOOD & CANCER, 2022, 69 : S328 - S329
  • [47] A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T- Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE)
    Weinkove, Robert
    George, Philip
    Fyfe, Robert
    Dasyam, Nathaniel
    Nouri, Yasmin
    Ostapowicz, Tess
    Mullins, Stefan
    Mester, Brigitta
    Giunti, Giulia
    Bollard, Catherine M.
    Perera, Travis
    Jina, Hayden
    D'Souza, Alwyn
    Qin, Le
    Ritchie, David S.
    Frampton, Chris M. A.
    Perret, Rachel
    Li, Peng
    Hermans, Ian
    BLOOD, 2023, 142
  • [48] LOCALLY MANUFACTURED AUTOLOGOUS CD19 CHIMERIC ANTIGEN RECEPTOR-T (CAR-T) CELLS FOR PHASE II PROSPECTIVE CLINICAL TRIAL FOR RELAPSED/REFRACTORY B-ACUTE LYMPHOBLASTIC LEUKAEMIA IN MALAYSIA
    Lim, T. S.
    Nyunt, W.
    Then, K.
    Cheong, S.
    Then, K.
    Ooi, G.
    Govindasamy, V.
    Idris, M. Mohd
    Azura, S.
    Abdullah, N.
    Zakaria, M. Muhd
    Chang, A. H.
    Ithnin, A.
    Wahid, S. S. Abdul
    CYTOTHERAPY, 2023, 25 (06) : S225 - S226
  • [49] Updated Phase 1 Results of Zuma-3: Kte-C19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    Wierda, William G.
    Bishop, Michael R.
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Castro, Januario E.
    Schiller, Gary J.
    Holmes, Houston
    Abedi, Mehrdad
    Ghobadi, Armin
    Arellano, Martha L.
    Malone, Adriana K.
    Pagel, John M.
    Mardiros, Armen
    Shen, Tong
    Vezan, Remus
    Jain, Rajul K.
    Shah, Bijal D.
    BLOOD, 2018, 132
  • [50] Updated Phase 1 Results of Zuma-3: Kte-X19, an Anti-CD19 Chimeric Antigen Receptor T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
    GWierda, William
    Bishop, Michael R.
    Oluwole, Olalekan
    Logan, Aaron C.
    Baer, Maria R.
    Donnellan, William B.
    O'Dwyer, Kristen M.
    Castro, Januario E.
    Schiller, Gary J.
    Holmes, Houston
    Abedi, Mehrdad
    Ghobadi, Armin
    Arellano, Martha L.
    Malone, Adriana K.
    Pagel, John M.
    Mardiros, Armen
    Shen, Tong
    Vezan, Remus
    Jain, Rajul K.
    Shah, Bijal D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
12345